Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
96 hedge funds and large institutions have $294M invested in Y-mAbs Therapeutics in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 34 reducing their positions, and 16 closing their positions.
8,125% more call options, than puts
Call options by funds: $329K | Put options by funds: $4K
2.94% more ownership
Funds ownership: 52.56% → 55.49% (+2.9%)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
3% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 34
0% more funds holding
Funds holding: 96 → 96 (0)
21% less capital invested
Capital invested by funds: $374M → $294M (-$79.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$22.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$19.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.94M |
| 4 |
BlackRock
New York
|
+$1.1M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.8M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.77M |
| 3 |
Goldman Sachs
New York
|
-$3.06M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.1M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$2.07M |
YMAB Hedge Fund Activity: Q2 2024 in Review
96 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2024, worth a combined $294M — down 21% from $374M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new YMAB positions and 16 closed out — a net gain of 1 holder — while 35 added to existing stakes and 34 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $22.1M. The largest seller was Point72 Asset Management, cutting an estimated $15.8M.
- 96 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $294M of Y-mAbs Therapeutics stock for Q2 2024, down 21% quarter-over-quarter.
- 17 funds opened new Y-mAbs Therapeutics positions in Q2 2024 and 16 closed out, a net change of +1 holder.
- The largest Y-mAbs Therapeutics buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $22.1M added.
- The largest Y-mAbs Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q2 2024.